John Patrick Shannon Jr. files SEC Form 4 disclosures for XERIS PHARMACEUTICALS INC. They have made 8 open-market trades across 2 companies since 2014, most recently 2026-08-01.
CIK 0001553595
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $505K since 2014, against 2 sales. Across 5 scored buys the stock is up 10.9% at ninety days, and 5.2 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| XERS | 2,898,933 | $29.9M |
| DRTX | 11,000 | — |
| Total | $29.9M |
Shares reported on the most recent Form 4, priced at the 2026-08-21 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 60% | 40% |
| Avg Move | +8.5% | -0.7% | +10.9% |
| Alpha | +9.1% | +0.8% | +5.2% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XERS | SELL | 2026-01-05 | 2026-01-06 | $7.08 | $176K | +7.1% | -1.6% | -13.8% |
| XERS | SELL | 2025-11-13 | 2025-11-17 | $7.46 | $347K | +0.0% | -2.6% | -3.8% |
| XERS | BUY | 2023-11-17 | 2023-11-17 | $1.64 | $101K | +1.6% | +8.2% | +75.4% |
| XERS | BUY | 2021-11-11 | 2021-11-12 | $2.10 | $210K | -7.2% | -6.8% | +5.5% |
| XERS | BUY | 2020-05-13 | 2020-05-14 | $3.55 | $78K | +50.0% | +25.3% | -11.1% |
| XERS | BUY | 2020-05-08 | 2020-05-11 | $3.20 | $25K | +19.5% | +32.7% | -7.1% |
| XERS | BUY | 2020-02-14 | 2020-02-18 | $4.15 | $50K | -21.4% | -62.7% | -8.4% |
| DRTX | BUY | 2014-08-12 | 2014-08-13 | $13.72 | $41K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.